SCIENTIA IN THE NEWS

Money Health: Go East, Young Man?

Brendon Nafziger, Writer, DOTmed
March 8, 2010

In this DOTmed article where Harry Glorikian, Scientia Advisors’ managing partner, is extensively quoted, Brendon Nafziger addresses the following timely question: Is China's mega 850-billion-yuan health care stimulus plan, coupled with a massive population beginning to succumb to Western diseases, a miracle for U.S. medical device makers, or a mirage? The article briefly discusses China’s health care stimulus plan and demand drivers, and point to issues companies wishing to enter the Chinese market may face, including domestic competition for medical devices, local laws and customs, as well as sustainability.

This report originally appeared in the February 2010 issue of DOTmed Business News

View more at:
DOTmed

Growth Spurts Ahead for China's IVD, HIT Markets

Brendon Nafziger, Writer, DOTmed
February 25, 2010

In this DOTmed article, Nafziger highlights the release of Scientia Advisors’ Industry Review entitled “Healthcare Market in China”. China is embarking on a multi-trillion Yuan project to ensure health care coverage of all its citizens while bringing its creaky health system into the 21st century. The article, based on the study’s findings and an interview with Harry Glorikian, Scientia’s managing partner, explains how massive an undertaking it truly is, and how much healthcare IT and diagnostics stand to benefit from the coming cash bonanza.



View more at:
DOTmed

Report: China’s healthcare spending to reach $600B by 2015

Omar Ford, Medical Device Daily Staff Writer
February 12, 2010

In this Medical Device Daily Article, Omar Ford, introduces a recent study by Scientia Advisors on the healthcare system in China which is likely to see big changes over the next few years. Driven by the government's 3 year reform plan to improve healthcare services, Harry Glorikian, managing partner at Scientia Advisors, states that "these updates to China’s healthcare system will help solidify the nation’s outdated system and have a tremendous impact on the economy." The article also highlights some of the major segments of growth such as the medical device, in vitro diagnostics and healthcare IT market areas.

View more at:
Medical Device Daily

Drug Companies Likely To Stay Cautious On Large Biotech Deals - Dow Jones article

Tom Gyrta , Dow Jones
January 15, 2010

In this article, based on interviews with Scientia Advisors Managing Partner Harry Glorikian, Mervyn Turner, chief strategy officer of Merck & Co (MRK), and others, Dow Jones reporter Tom Gyrta concludes that while biotechnology drugs will continue to be of interest to drug companies, "risk averse pharmaceutical giants" are likely to "remain cautious" about large biotech deals.

In the article, Glorikian points out that "pharmaceutical companies are hesitant to spend too much for technology with which they have limited experience and which is expensive to develop. They are easing into it." What is more, he says, recent manufacturing problems at Genzyme Corporation (GENZ) have made pharma companies wary of biotechnology's complexities in comparison with the simpler production of chemical pharmaceuticals taken in pill form. As a compromise, many Scientia pharmaceutical clients are looking into "biosimilars"--generic versions of biotechnology drugs--to reduce development risk.

The article also describes recent biotech deals, buyout speculation regarding companies with potential blockbuster products, and companies' concerns about possible overspending, regulatory risk and uncertain market adoption.


Biotech IPOs on the rise in Mass

Julie M. Donnelly, Mass High Tech
January 14, 2010

Following a lengthy, quiet period for biotech initial public offerings (IPOs), activity has been picking up nationwide with four successful biotech IPOs in the second half of 2009. In Massachusetts, two Cambridge-based companies have recently registered for initial public offerings. In this article, Harry Glorikian, managing partner of Scientia Advisors, comments on the timing of one of these recent IPOs: “Aveo Pharmaceuticals filed for an IPO when the time was ripe. These deals allowed the company to develop its platform technology using capital from partnerships, rather than from issuing a premature IPO when the company and technology were still in their infancy.”


View more at:
Mass High Tech

Scientia in Federal Computer Week - Government Funding, Technological Advances Transform Healthcare

Barbara DePompa, 
January 4, 2010

An evolution is taking place with health IT beginning to be part of the culture for providing healthcare. This article highlights Scientias’ market projection for health IT to support the evidence of the current growth wave: “Health IT will grow at a combined annual growth rate of 11 percent through 2013, according to consulting firm Scientia Advisors. The firm projects health IT will be the fastest growing segment of the $1 trillion global healthcare market, expanding from $35 billion in 2008 to more than $60 billion by 2013.” The author goes on explaining how many key technological tools and/or services are contributing to the current growth wave, in addition to government funding.


View more at:
Federal Computer Week

HIT Fastest Growing Segment of Global Health Care Market

Advance for Health Information Executives
December 24, 2009

In this Advance article, the release of Scientia Advisors' Health Information Technology (HIT) Industry Review is highlighted, including its findings that HIT is the fastest growing segment of the $1 trillion global health care market, and that its double-digit annual growth rate is likely to continue through 2013. Harry Glorikian, managing partner, is quoted stating that "Historically, therapeutics and medical devices have captured more than 90 percent of the worldwide health care product sales. But, with declining marginal benefits from new interventional products and greater emphasis on appropriate use of existing interventions, we project accelerating HIT-related sales." The article also points to key trends and growth drivers.

State of the Industry Review

Rebecca Wright, Nutraceuticals World
December 1, 2009

In this article, executives reflect on the past year in nutraceuticals and look ahead to what the future might bring. Bob Jones, Principal at Scientia Advisors, leads with the following insight on the state of the industry: “A few years ago, when I talked with major food companies about functional ingredients, what I mostly saw was polite interest, but no real commitment. That is, everyone acknowledged making products that promoted health was a virtuous endeavor, but very few felt an urgent need to take the plunge. That’s beginning to change. We now see major companies throughout the value chain committing real resources—staff, time and money—to creating ingredients and finished goods that provide a health benefit beyond basic nutrition. And some are putting products into the marketplace. We may be approaching a ‘tipping point’.”


View more at:
Nutraceuticals World

H1N1 Boosts Development in Pharma Sector - Many Factors, Chief Among Them a Potential Pandemic, Are Fueling Vaccine Resurgence

Rod Raynovich, Genetic Engineering & Biotechnology News
December 1, 2009

The potential H1N1 pandemic has drawn renewed interest in vaccines. This article by Rod Raynovich in Genetic Engineering & Biotechnology News reviews the vaccine market, its major players and the emerging companies with new technologies. Scientia Advisors' global vaccines market annual growth forecast of 12% from 2008 through 2014 is cited in the article, as well as the company’s growth projections in the viral and the pediatric bacterial vaccine sectors.

HIT to Become a $60 B Market by 2013

Brendon Nafziger, Writer, DOTmed
November 11, 2009

In this DOTmed article, Nafziger highlights the release of Scientia Advisors' Health Information Technology (HIT) Industry Review. The HIT market is on the fastest growing markets in healthcare today with $35Bn today, growing at 11% to reach $60Bn in 2013. Much of the drive for HIT adoption stems from the government incentives put in place in an effort to improve healthcare. Harry Glorikian, managing partner, is quoted, "Hospitals are adopting them at various levels. It's becoming a must-have." The article points of some of the key insights in the review such as the rise of HIT in emerging economies like China, and the potential of the clinical decision support system (CDSS) market.

View more at:
DOTmed

Boom Times For Health IT Sector: The healthcare IT marketplace is growing by 11% annually, which will likely continue through 2013, says a study from Scientia Advisors

Mitch Wagner, Information Week
November 11, 2009

In this Information Week article, Wagner highlights the release of Scientia Advisors' Health Information Technology (HIT) Industry Review. The HIT market is on the fastest growing markets in healthcare today, showing 11% growth. The article points out some of the key insights in the review including the need for in-patient and out-patient EHRs, market dynamics, buying preferences of hospitals and key growth segments such as CDSS.

View more at:
Information Week

Healthcare Finance News--Consultant: Healthcare IT market to grow 11 percent per year through 2013

Bernie Monegain, Contributing Editor, Healthcare Finance News
November 10, 2009

In this Healthcare Finance News article, Monegain highlights the release of Scientia Advisors' Health Information Technology (HIT) Industry Review. The HIT market is on the fastest growing markets of the $1Tn healthcare market today and growing at 11% to 2013. Harry Glorikian, managing partner, is quoted, "Historically, therapeutics and medical devices have captured more than 90 percent of worldwide healthcare product sales. But with declining marginal benefits from new interventional products and greater emphasis on appropriate use of existing interventions, we project accelerating HIT-related sales." The article points out some of the key insights in the review including the demand for in-patient and out-patient EHRs, market dynamics, buying preferences of hospitals and key growth segments such as CDSS.

View more at:
Healthcare Finance News

Cosmetics Design--Massive growth in cosmeceuticals leads to ingredients shortage

Simon Pitman, Cosmetics Design
November 9, 2009

In this Cosmetics Design article, Pitman highlights the cosmeceuticals market and the need in this market for new innovative ingredients. He sources this conclusion from Scientia Advisors' recent release of a Cosmeceuticals market industry review, pointing out that the category is growing at twice the pace of the cosmetics industry in both the US and worldwide, but the development of technologically advanced active ingredients is not keeping up with the growth. He also highlights some of market dynamics in changing consumer trends, geographic breakdown and government regulation.

View more at:
Cosmetics Design

The London Independent--As populations age, demand for 'cosmeceuticals' expected to rise

The London Independent
November 6, 2009

This London Independent article highlights the release of Scientia Advisors' new cosmeceuticals market industry review. Cosmeceuticals which are cosmetics which provide health benefits, is highlighted in the review as a fast growing area of personal care products. Within it, skincare is one of the fastest growing segments. Overall demand for these products are expected to increase as a age-conscious populations begin to age.

Medical Device Daily--Scientia Study shows selfcare growing for delivery devices

Omar Ford, Staff Writer, Medical Device Daily
November 5, 2009

In this Medical Device Daily article, Omar Ford highlights the release of Scientia Advisors' new parenteral market industry review. He explains that parenterals, which is a method of mechanically delivering drugs, is a $11.8Bn market growing at 7% to 2012. Within parenterals, the article highlights key insights from the review on the high growth in the consumer sector due to the increase in home health, the potential for this to decrease overall healthcare spending and even the migration of these technologies from the healthcare to nutrition.

View more at:
Medical Device Daily

Featured Article: Pharmacogenomics

Jeffrey M. Perkel, Biocompare
November 2, 2009

In this Biocompare article, Jeffrey Perkel provides an overview of what pharmacogenomics is. The name of branch of genetics has received significant hype over the last decade and it's definition has also expanded considerably. It has become to mean the use of various biomakers (DNA, RNA, protein) in diagnostics in order to predict positive response or adverse reaction to a pharmaceutical drug."It's the use that's classifying it, not the word genomic," explains Harry Glorikian, managing partner at Scientia Advisors. Perkel highlights many of the pharmacogenomic tests that are currently available and their performance in healthcare. He concludes that despite the current lack of pickup of the industry, the future of pharmacogenomics is positive.

View more at:
Biocompare

Confusing Choices for Doctors and Type 2 Diabetes Patients:
Drugs in development and on the market are dogged by serious side effects.

Patricia F. Dimond Ph.D., Genetic Engineering & Biotechnology News
October 23, 2009

It’s no doubt that diabetes has become a major healthcare concern worldwide. This article by Dr. Patricia Dimond, in Genetic Engineering & Biotechnology News reviews the treatment options today and confusion for both physicians and patients over what is safe and effective. In the article, Dimond highlights the risks of the more aggressive or intensive insulin treatments and the lack of safer options from the pharmaceutical companies many of which have received black box warnings or suspensions due to risks of complications. Scientia Advisors' managing partner Harry Glorikian is quoted in the article stating that, "We expect that as more drugs go generic, incretin mimetics (which increase insulin secretion) and insulins will generate an increasing share of the revenues. Therapies with benefits beyond glucose management (such as delaying the onset of diabetes or treating co-morbid conditions) will be used earlier in treatment. For a variety of reasons, despite the growing availability of new types of drugs, various forms of insulin will remain the gold standard."

Scientia comments on vaccine industry for CBS Evening News

Jim Axelrod, CBS News
October 22, 2009

Harry Glorikian, managing partner at Scientia Advisors along with other experts in the healthcare industry such as Dr. Martin Blaser, Chair of Medicine at NYU Langone Medical Center and Daniel Adams, CEO of Protein Sciences Corp comment on the H1N1 vaccine in Jim Axelrod's CBS Evening News report.

View more at:
CBS Evening News

Boston Globe--For drug makers, a shot in the arm: The quest for an H1N1 vaccine has been good business for some firms

Robert Weisman, Boston Globe
October 21, 2009

In this article, Robert Weisman delves into impact of the H1N1 vaccine push has had on vaccine-makers such as Novartis. He points out that in addition to the actual revenue garnered from the vaccine, the headway made in developing new research and streamlining of the production of vaccines, either by organic growth or acquisition, will be beneficial to the companies in future vaccine development. Scientia Advisors' global vaccines market projections, from $16 billion in 2007 to $35 billion in 2014, is cited in the article. Scientia Advisors' Managing Partner, Harry Glorikian was also quoted in the article pointing out the potential opportunity for vaccine makers in China which is planning on a national vaccine program.

View more at:
Boston Globe

Fierce Vaccines--Swine flu hands vax industry $7B windfall

John Carroll, Fierce Vaccines
October 21, 2009

In this article, John Carroll highlights the potential $7 billion windfall reported by the Boston Globe. Scientia Advisors' estimate of the vaccine market is also highlighted in the Boston Globe article as jumping from $16 billion in 2007 to $35 billion in 2014.

View more at:
Fierce Vaccines

GenomeWeb--CombiMatrix Hires Baird to Provide 'Strategic Advice' in Buyers' Market

GenomeWeb Staff, GenomeWeb
September 22, 2009

This article in GenomeWeb, focuses on the CombiMatrix and its recent decision to hire an investment bank, Baird to outline its future strategy. Harry Glorikian, managing partner at Scientia Advisors, is quoted in the article offering insight into the existing market situation stating that, "There are two ways to get yourself out of this existing market situation and one of them is to make very strategic smart acquisitions at good valuation that, as the market starts to turn, give you the ability to step out there."

View more at:
GenomeWeb

GenomeWeb: ProteoMonitor--Recent Deals Suggest Proteomics, Life-Science Markets May be Poised to Renew M&A Activity

ProteoMonitor Staff, GenomeWeb
September 21, 2009

This ProteoMonitor article highlights the recent surge of M&A activity in the proteomics markets which has suggested to many, a trend towards consolidation. The article highlights two deals in particular: a bid by Danaher to buy ABI/MDS mass-spec joint venture and MDS Analytical Technologies, and Agilent's bid for Varian. Scientia Advisors managing partner, Harry Glorikian is quoted in the article providing some insight into the drivers behind these acquisitions; pointing out potential growth opportunities that these acquisitions open up for the companies.

View more at:
GenomeWeb: ProteoMonitor

GenomeWeb: ProteoMonitor--Tale of Danaher: From Crippled Real Estate Investment Trust to Mass Spec Top Banana

Tony Fong, GenomeWeb
September 16, 2009

In this ProteoMonitor article, Tony Fong offers some details into Danaher, who's recent bid to buy the ABI/MDS mass-spec joint venture and MDS Analytical Technologies has vaulted it into the spotlight. Fong outlines the history and background of Danaher and the significant moves that it's made to build up its life sciences business over the last few years. Harry Glorikian, managing partner at Scientia Advisors was quoted stating "They're not making small moves. They're making very bold moves that give them a solid position within a growth market."

View more at:
GenomeWeb: ProteoMonitor

Biomedical Business & Technology--Harry Glorikian, Consulting firm founder, Helping mold the future for med-tech firms

Jim Stommen, Contributing Editor, Biomedical Business & Technology
September 1, 2009

In this Biomedical Business & Technology (BB&T) article, Jim Stommen, interviews Harry Glorikian, founder and managing partner of Scientia Advisors. In the interview, Stommen probes many of the high profile issues in healthcare today including venture capital investments since the crisis, healthcare reform and what it means in terms of opportunities for companies, how companies should deal with the changing healthcare environment. The interview also goes into more detail about the diagnostics world, including molecular diagnostics, personalized medicine, imaging, and nanotechnology.

View more at:
Medical Device Daily.

LA Times--Medical testing in your home: Forget the office visit. Home-health exams can save time and money, and give patients some control.

Kathleen Kelleher, LA Times
August 31, 2009

In this LA Times article, Kathleen Kelleher focuses on the developing new market of home or direct to consumer diagnostic testing. These tests are available for the consumer to directly purchase it from a lab or pharmacy and the results are then provided to the consumer. This reduces the potential cost of a doctor's visit and allows the patient to have more control and feel empowered about their health.Scientia Advisors, an international consulting firm is cited in the article sizing the potential market for this type of home health over-the-counter testing, which is growing at 7-8% a year. In addition to pointing out the potential of home testing, the article also stresses the importance to still get guidance on treatment from a doctor, especially for prescription medications.

View more at:
LA Times

Medical Device Daily--Growing neurostimulation sector is opportunity for device makers

Lynn Yoffee, Medical Device Daily
August 21, 2009

In this Medical Device Daily article, Lynn Yoffee announces the release of a new study by Scientia Advisors. The study focuses on the nascent neurostimulation market which currently, is growing at double digit growth rates. Harry Glorikian, managing partner at the firm, commented on this market stating that “It’s a new way of approaching the disease state – a solution that has eluded drugs and surgery.” The study highlights the significant potential of the neurostimulation market, which promises to circumvent a lot of the downsides that have plagued drugs and surgical treatment option such as nasty side-effects and irreversibility. The article highlights some of the details from the study such as the size and growth of the market as well as three largest segments of neurostimulation market. The study itself, which is expected to be released later this month, predicts positive outcomes for patients and device makers.

View more at:
Medical Device Daily

The Marker -- Who will gain from the chronic problems of the US? (trans.)

Paz Vaysman, The Marker
August 19, 2009

This article in The Marker, an Israeli news publication, focuses on the wound care market. It highlights the American healthcare reform and the problem hospitals are facing to find faster and cheaper solutions for wound care. Using a data from study by Scientia Advisors, the article highlights the steady growth of this market and potential opportunities in this market. The article also points out six Israeli companies concentrating in this area with descriptions of the company and key products: Lifewave, HealOr, MacroCure, Q Ray, MediWound, MediWound.

View more at:
The Marker

Mass High Tech--Life sciences startups launching despite recession

Julie M. Donnelly, Mass High Tech
August 14, 2009

In this Mass High Tech article, Julie Donnelly focuses on the recent movement in the venture capital landscape. Despite the recession, several life science startups have launched and are thought to have a better shot at profitability. Harry Glorikian, managing partner at Scientia Advisors, points out that "The pace of deals is slower, but investors still have to put their money somewhere" and that firms are being creative in where they get their funds. The article highlights three companies: Acetylon Pharmaceuticals Inc., Forma Therapeutics Inc., and Targ-anox, Inc, who have been successful in getting funding, each in a different way.

View more at:
Mass High Tech

Medical Device Daily--Consulting firm head sees opportunity in reform effort

Jim Stommen, Medical Device Daily Contributing Writer
July 28, 2009

In this Medical Device Daily article, Jim Stommen highlights several points made by Harry Glorikian, managing partner at Scientia Advisors, on the potential opportunity of the current market. In a wide-ranging question-and-answer interview session, which will be published at a later date, Glorikian comments on the perspective and approach that companies should have in managing product portfolios and development efforts in order to take advantage of the current economic crisis and reposition themselves for future growth.

The full version of the interview session will be published in Medical Device Daily's sister publication, Biomedical Business & Technology in the September issue.

View more at:
Medical Device Daily

Agilent Plans to Buy Varian for $1.5 Billion to Expand Footprint in Life Sciences

Tony Fong, Genome Web
July 27, 2009

This Genome Web article covers Agilent's recent announcement to a spend $1.5 Bn to purchase Varian. Harry Glorikian, managing partner at Scientia Advisors, is quoted in the article with his view on the announcement. Glorikian states that the purchase will benefit Agilent by expanding its product portfolio but that the purchase's true value will be realised after Agilent successfully integrates the purchase and develops a strategy for its push into life sciences.

View more at:
Genome Web

Medical Device Daily--Scientia says opportunities abound in peripheral sector

Jim Stommen, Executive Editor, Medical Device Daily
June 25, 2009

In this Medical Device Daily article, Jim Stommen puts the spotlight on a study performed by Scientia Advisors on the peripheral vascular disease (PVD) sector of the healthcare market. In it, Stommen points out some of the key takeaways from the study such as the high growth potential of several segments within the PVD market including chronic venous insufficiency (CVI) and thrombosis diagnosis and treatment. Harry Glorikian, Scientia's managing partner, is also quoted in the article pointing out that companies are missing potential opportunities: "Major companies are missing possibilities that could significantly improve the health and well-being of aging global populations, cut healthcare costs, and boost their own bottom lines."


Scientia Advisors regularly conducts and publishes studies into market areas which have significant growth potential. These studies help Scientia deepen their understanding of different areas of healthcare which may have gone unnoticed by others. These studies also allow Scientia to enhance their process. A synopsis of the study referenced above can be found here. Other Scientia market overviews can be found here.

View more at:
Medical Device Daily

Xconomy -- Biogen and Fellow Boston-Area Biotechs Ready for Biogenerics

Ryan McBride, Xconomy
June 24, 2009

This Xconomy article, focuses on the dynamics of the growing biosimilars market. This nascent market is referred to by many names: biogenerics, bio-betters, and follow-on biologics, to name a few. Scientia Advisors' partner, Amit Agarwal, comments on the interest this market has drawn from companies with biologics capabilities: “What we’re seeing is that they are at least considering this market. It’s out there and it’s not just coming from the usual suspects.” The article also points out some of the key areas of debate surrounding this developing market and highlights some companies making moves in this space.

View more at:
Xconomy

BioWorld -- Patents: Lifeblood of Biotech or a Cancer to Innovation?

Anette Breindl, BioWorld: Financial Watch
May 25, 2009

BioWorld's article addresses the controversy surrounding the patenting of human genes in light of the recent lawsuit by the American Civil Liberties Union and others against the Utah based biotech company Myriad Genetics and the University of Utah Reasearch Foundation.

The lawsuit highlights an ongoing debate on whether or not the current patent system stifles or encourages innovation. Scientia Advisors' managing partner Harry Glorkian is quoted in the article, stating that “the point of filing is to make information public and encourage others” to use that information for further innovation.

The article also highlights the actions of large pharma company GlaxoSmithKline to combat the decline in drug discovery innovation via collaborations and releasing information into the public domain. Some critics attribute the decline of innovation in drug discovery to the Bayh-Dole Act. Scientia’s Glorikian was quoted stating that he, as well as others at Scientia, “have never seen any data connecting the two,” and instead related the decline in drug discovery productivity to “a host of other factors” including patient stratification and a changing regulatory landscape."

View more at:
BioWorld

Science interviews Harry Glorikian in "Molecular diagnostics: Personalizing personalized medicine"

Jeffrey M. Perkel, Science
May 8, 2009

The journal Science interviews Scientia's Harry Glorikian regarding developments within the molecular diagnostics arena.

View more at:
Science

MDx will drive personalized medicine

Vicki Glaser, Genetic Engineering & Biotechnology News
April 1, 2009

Scientia Advisors discusses how diagnostics and innovation will play a role in reducing future healthcare costs.

Scientia, a Life Sciences Management Consulting Firm, Provides Answers, Not Questions

Wade Roush, Xconomy
March 10, 2009

Wade Roush from Xconomy comments on what sets Scientia apart from other management consulting firms.

View more at:
Xconomy

The Wall Street Journal uses Scientia Advisors' medical device market growth estimates

Alicia Mundy, The Wall Street Journal
March 6, 2009

In the article, "Political Lobbying Drove FDA Process," WSJ writer Alicia Mundy referenced market growth estimates derived by Scientia Advisors for the medical device industry.

View more at:
The Wall Street Journal

When drugs get personal

Med Ad News
February 1, 2009

With the emergence of drug/diagnostic combinations, the issues surrounding the marketing of these products are increasingly becoming important to pharmaceutical companies.

In this article, by Joshua Slatko, Scientia’s Amit Agarwal, provides insight into possible marketing strategies and the integral role of physicians in this effort. “This means that the market /sales effort must be about helping physicians understand the disease in all its variations and then educating physicians about clinical treatment guidelines,” he says.

Additionally, Agarwal points to older, already marketed products, as having substantial potential for drug/diagnostic combinations and as being a cost effective way of boosting sales of already marketed drugs. Agarwal comments, “The diagnostic/drug approach is a very cost effective way to boost the sales of non-blockbuster drugs that the standard life-cycle management approaches (reformulation, indication expansion, and sales-force expansion) do not work well for.”


View more at:
Med Ad News

Expert: Diagnostics could increase drugmakers' revenue

BIO SmartBrief
January 14, 2009

Scientia's Amit Agarawal discusses how major pharmaceutical firms could increase their earnings and boost patient health by marketing diagnostic tools alongside their existing products.

View more at:
BIO SmartBrief

New Personalized Medicine Model Proposed

United Press International
January 13, 2009

Amit Agarwal, partner at Scientia Advisors, recommends new strategies for pharmaceutical firms seeking to find alternative uses for their already approved therapeutics.

Bob Jones of Scientia Advisors Discusses the Growth of the Functional Foods Market

Dan Mitchell, BNET Food
January 5, 2009

Bob Jones, principal at Scientia Advisors, discusses important case studies and trends driving the growth of the functional foods market.

View more at:
BNET Food

Principal Bob Jones interviewed on Public Radio International's "The World"

Lisa Mullins, PRI's The World
January 5, 2009

The use of so-called functional foods, is on the rise, especially in China and Japan. Functional foods are those fortified with additional vitamins or minerals. Anchor Lisa Mullins speaks with Bob Jones of the management consulting firm Scientia Advisors about why one country will accept a particular functional food and another will reject it.



View more at:
The World

Scientia Forecasts Bright Future for Functional Foods

Food Product Design
December 18, 2008

Food Product Design interviews Bob Jones, principal at Scientia Advisors, on the reasons for growth within the functional foods market.

View more at:
Food Product Design

Scientia Advisors Reports on the Future of Functional Foods

Boston Business Journal
December 17, 2008

The Boston Business Journal highlights important insights made by Scientia Advisors on the growth of the functional foods market.

View more at:
Boston Business Journal

Scientia Advisors Addresses the Impact of Decentralized Healthcare on the IVD Industry

Q1 Productions
November 24, 2008

Harry Glorikian, managing partner at Scientia Advisors, highlights how the emergence of point-of-care centers will empower patient consumers and revolutionize the healthcare market, including the IVD industry.

View more at:
Q1 Productions

Scientia's Glorikian Discusses Next Generation Sequencers and their Applications

Justin Petrone, BioArray News
November 4, 2008

Scientia Advisors speaks about applications for next generation sequencers and warns of threats these sequencers will pose to diagnostic businesses.


View more at:
BioArray News

Array-Based Dx Shops See Asia as One Promising Route to Global Marketplace

Justin Petrone, BioArray News
November 4, 2008

European companies Mordiag and DiaGenic have announced tentative plans to pursue the launch array-based tests in China or India in addition to an initial launch in Europe. Harry Glorikian, managing partner at Scientia Advisors comments on this new push into these emerging markets.

View more at:
BioArray News

Scientia Advisors Discusses Microarrays, Molecular Dx, the Global Healthcare Market

BioArray News
October 28, 2008

Harry Glorikian, managing partner at Scientia Advisors provides expert opinion and in-depth analysis on the array-based diagnostics market, elaborating on key trends and insights into the molecular diagnostics market.

View more at:
BioArray News

Scientia's Glorikian Comments on Invitrogen’s Acquisition of Applied Biosystems

GenomeWeb Daily News
June 12, 2008

Harry Glorikian, managing partner at Scientia Advisors, analyzes the merger between Invitrogen and ABI, noting that the life science tools market will remain competitive due to the presence of new technologies by smaller companies.

View more at:
GenomeWeb

Scientia Advisors Provides Insight into the Molecular Diagnostics Market as New Players Emerge

Celia Lamb, Sacramento Business Journal
July 20, 2007

Scientia Advisors describes the potential opportunity for genetic analysis tools companies within the molecular diagnostics market.

Amid Molecular Dx Acquisition Trend, Some View Cepheid as Prime Target

Edward Winnick, GenomeWeb
July 11, 2007

Scientia Advisors highlight several companies that may be looking to move into the molecular diagnostics space via an acquisition of Cepheid because of its FDA-approved real-time PCR-based molecular diagnostics platform.

View more at:
GenomeWeb

Scientia's Agarwal Comments on the Strong Growth of Blood-Glucose Monitor Company

Ryan McBride, Mass High Tech
June 24, 2007

Amit Agarwal, partner at Scientia Advisors, compares the strong performance of AgaMatrix to the overall diabetes monitoring market.

View more at:
Mass High Tech

Biogen plans in-house incubator to tap new products

Ryan McBride, Mass High Tech
December 25, 2006

Scientia Advisor’s managing partner, Harry Glorikian, comments on Biogen Idec’s proposed strategy to form an incubator to develop an existing early start-up.

View more at:
Mass High Tech

Growth in Mass Spec Sales Helps Proteomic Market Grow Slow and Steady, Report Finds

Tony Fong, GenomeWeb
December 7, 2006

Harry Glorikian describes the drivers behind growth in the mass spectrometry market.

View more at:
GenomeWeb

Local conditions and national concerns within the European IVD market

John Conroy, IVD Technology
September 1, 2006

Harry Glorikian, managing partner at Scientia Advisors, highlights specific drivers and trends affecting the European IVD market.

View more at:
IVD Technology

What’s Next for Stem Cell Companies?

Charles Jennings, Pharma Drug Discovery
July 24, 2006

Scientia Advisors comments on the emerging field of cell-based therapy.

View more at:
Pharma Drug Discovery

Along with Growth Opportunities, Molecular Dx Market Likely to Bring a Wave of Consolidation

Edward Winnick, GenomeWeb
April 12, 2006

Scientia Advisor’s managing partner, Harry Glorikian, forecasts a wave of M&A activity as larger companies seek to a build a molecular diagnostics portfolio.

View more at:
GenomeWeb

Roche's patent expiration opens US market

DrugResearcher.com
March 30, 2006

Scientia Advisors managing partner, Harry Glorikian, describes how Roche’s patent expirations will affect companies such as Applied Biosystems.

View more at:
Drug Researcher